Telos Capital Management Inc. Raises Stake in Merck & Co., Inc. $MRK

Telos Capital Management Inc. boosted its position in Merck & Co., Inc. (NYSE:MRK) by 7.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 15,848 shares of the company’s stock after acquiring an additional 1,071 shares during the period. Telos Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $1,255,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of MRK. Legend Financial Advisors Inc. bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at about $25,000. CBIZ Investment Advisory Services LLC increased its position in shares of Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after buying an additional 221 shares during the period. Mountain Hill Investment Partners Corp. bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at about $43,000. Advantage Trust Co increased its position in shares of Merck & Co., Inc. by 57.1% during the second quarter. Advantage Trust Co now owns 550 shares of the company’s stock valued at $44,000 after buying an additional 200 shares during the period. Finally, Chung Wu Investment Group LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at about $45,000. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MRK has been the topic of several research analyst reports. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Wells Fargo & Company reduced their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. Finally, Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $104.33.

Merck & Co., Inc. Price Performance

MRK opened at $86.15 on Monday. The stock has a 50-day moving average price of $84.57 and a 200-day moving average price of $81.86. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The firm has a market cap of $215.17 billion, a PE ratio of 13.27, a P/E/G ratio of 0.95 and a beta of 0.37. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. The business had revenue of $17.28 billion during the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.